Fig. 4: Loss of HDAC1 protein or HDAC1 catalytic activity causes changes in the immunophenotype.

A Percentage of ALK+ cells in end-stage thymic tumors of different genotypes (NPM::ALK n = 6, NPM::ALK Hdac1KO n = 5, and NPM::ALK Hdac1KI n = 4) assessed by FACS. The horizontal line represents the average percentage of positive cells of biological replicates for each genotype. B Average distribution of markers for double negative (DN; CD4^-CD8^-), double positive (DP; CD4⁺CD8⁺), CD4⁺ and CD8⁺ cells among ALK+ cells in end-stage thymic tumors of indicated genotypes: NPM::ALK n = 6, NPM::ALK Hdac1KO n = 5 and NPM::ALK Hdac1KI n = 4. C Average percentage of ALK+ cells exhibiting features of double negative 1 (DN1), double negative 2 (DN2), double negative 3 (DN3), and double negative 4 (DN4) cells in end-stage thymic tumors of different genotypes: NPM::ALK n = 6, NPM::ALK Hdac1KO n = 5 and NPM::ALK Hdac1KI n = 4. D The average percentage of ALK+ cells exhibiting features of CD4 naïve (CD4⁺ CD62L^high CD44^low), CD4 effector (CD4⁺ CD62L^low CD44^high) or CD4 central memory T cells (CD4⁺ CD62L^high CD44^high) in end-stage thymic tumors of different genotypes: NPM::ALK n = 6, NPM::ALK Hdac1KO n = 5 and NPM::ALK Hdac1KI n = 4. E Average percentage of ALK+ cells exhibiting features of CD8 naïve (CD8⁺ CD62L^high CD44^low), CD8 effector (CD8⁺ CD62L^low CD44^high) or CD8 central memory T cells (CD8⁺ CD62L^high CD44^high) in end-stage thymic tumors of different genotypes: NPM::ALK n = 6, NPM::ALK Hdac1KO n = 5 and NPM::ALK Hdac1KI n = 4. F Percentage of ALK+ cells expressing TCRb in end-stage thymic tumors of different genotypes. The horizontal line represents the average percentage of positive cells of biological replicates for each genotype. Groups were compared using one-way ANOVA corrected for multiple comparisons using GraphPad Prism version 8.4.3. Statistical significance is indicated by *** for p < 0.001. G Percentage of ALK+ cells in the spleen (left) and bone marrow (right) isolated from mice of different genotypes presented with end-stage thymic tumors. The horizontal line represents the average percentage of positive cells of biological replicates for each genotype: NPM::ALK n = 5 (left) and NPM::ALK n = 6 (right), NPM::ALK Hdac1KO n = 5 and NPM::ALK Hdac1KI n = 4. H Percentage of ALK+ cells expressing TCRb in the spleen (left) and bone marrow (right) isolated from mice of different genotypes presented with end-stage thymic tumors. The horizontal line represents the average percentage of positive cells of biological replicates for each genotype: NPM::ALK n = 5, NPM::ALK Hdac1KO n = 5, and NPM::ALK Hdac1KI n = 4.